α6GABAA receptor-selective positive allosteric modulator as a novel therapy for fibromyalgia: A proof-of-concept study in mice modeling chronic widespread musculoskeletal pain

Neurotherapeutics 2026 Open access

Read full text
Authors: Myles Sant-Cassia, Cheng-Han Lee, V. V. N. Phani Babu Tiruveedhula, James Cook, Chih-Cheng Chen, Lih‐Chu Chiou
DOI: 10.1016/j.neurot.2026.e00956
Cited by: 1
References: 94

Abstract

R-selective positive allosteric modulator, such as DK-I-56-1, is a potential strategy for fibromyalgia pain management as monotherapy or as adjuncts to gabapentinoids.

Fields of Study & Subjects

Pain Mechanisms and Treatments Fibromyalgia and Chronic Fatigue Syndrome Research Nicotinic Acetylcholine Receptors Study

Publication details

Journal / source
Neurotherapeutics
Publisher
Elsevier BV
Volume
23
Issue
4
Pages
e00956–e00956
Publication date
1 July 2026
Language
EN